BCMA-Targeting Agents in the Treatment of Multiple Myeloma: Right Patient, Right Time

home / insights / bcma-targeting-agents-in-the-treatment-of-multiple-myeloma-right-patient-right-time

An overview of the role of currently-available and emerging BCMA-targeting therapies in the treatment landscape for multiple myeloma.

EP. 1: Treatment Approach for a 57-Year-Old Man With Triple-Class Refractory MM

Sagar Lonial, MD, FACP;Karen L. Klugo, MD;Natalie Callander, MD

February 28th 2022

Sagar Lonial, MD, FACP, highlights a novel treatment option available for a 57-year-old man whose disease progresses after 3 prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

EP. 2: BCMA-Targeting Belantamab Mafodotin: Role in the Treatment Landscape of RRMM

Sagar Lonial, MD, FACP;Karen L. Klugo, MD;Natalie Callander, MD

February 28th 2022

The rationale for treating relapsed/refractory multiple myeloma with belantamab mafodotin, and studies investigating the drug’s potential in earlier treatment settings.

EP. 3: Safety of Belantamab Mafodotin in Patients With RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 8th 2022

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

EP. 4: Management of a 61-Year-Old Female With Heavily Pretreated RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 8th 2022

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

EP. 5: Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 14th 2022

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

EP. 6: Belantamab Mafodotin Dosing Strategies in Patients with RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 14th 2022

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

EP. 7: Treatment of Keratopathy Associated with Belantamab Mafodotin

Sagar Lonial, MD, FACP;Karen L. Klugo, MD;Natalie Callander, MD

March 21st 2022

Recommendations for managing ocular toxicities associated with belantamab mafodotin when used as treatment for relapsed/refractory multiple myeloma.

EP. 8: CAR T-Cell Therapy for RRMM

Sagar Lonial, MD, FACP;Karen L. Klugo, MD;Natalie Callander, MD

March 21st 2022

Implications for treating patients with relapsed/refractory multiple myeloma with CAR T cells vs antibody-drug conjugates.

EP. 9: BCMA-Targeting Bispecifics for the Treatment of RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

EP. 10: Sequencing BCMA-Targeted Therapies in RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

EP. 11: BCMA-Targeting Therapies for RRMM: Future Perspectives

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.